Tag: Stelfonta

In a pivotal clinical trial, a single injection of Stelfonta led to complete tumor resolution in 75% of treated dogs within 28 days. What is Stelfonta? This injectable medication, also known as tigilanol tiglate, is a veterinary treatment option for certain non-metastatic mast cell tumors (MCTs) in dogs, offering a non-surgical alternative for hard-to-reach or difficult-to-excise tumors.

While the term 'MCT injection' might sound unfamiliar, it encompasses several distinct medical and veterinary applications, from using medium-chain triglycerides as a drug carrier for injectable hormones to a specific treatment for mast cell tumors in dogs. Understanding the context is crucial to determine what is an MCT injection, as the meaning is not universal across medicine.